This fall, Fierce Pharma Marketing launched a running series of Q&A features celebrating up-and-comers in our corner of the industry. Each of the “Rising Stars” profiles spotlights a different ...

Drug names are complicated things. For one, they must linguistically fulfill the role of being a shiny bauble for prescribers ...

People in pharma suffer from a very particular type of marketing anxiety that’s hard to explain to people outside of the industry. It goes something like this: Your organization is sitting on a ...

Pharmaceutical companies are spending more on marketing than ever before, driven by factors including the aging of the population, the increased prevalence of chronic disease and the growing ...

In the not too distant past, pharma lagged behind consumer advertising’s ability to churn out cutting-edge creativity. Weighed down by the regulatory, safety and compliance aspects that are par for ...

More pharma companies are launching direct-to-consumer drug platforms and the rise of these self-pay services could improve ...

The Austin-based startup founded by industry leaders accelerates time to market, enhances efficiency, and reduces costs for pharmaceutical companies through AI-driven automation of medical, legal, and ...

n the fast-paced world of pharmaceutical marketing, translating content for global audiences is not a simple task. It involves more than just translating words from one language to another; it ...

Blockbuster drugs such as Lipitor, Cozaar, Crestor, among others, used to enable big-name pharmaceutical companies marketing rights and exclusivity in producing those drugs under long-term patents. In ...

Pharmaceutical marketing is undergoing a hard reset. Tougher transparency rules, louder scrutiny of D2C ads, and political pressure on GLP-1s, telehealth, and drug pricing are all hitting at once. The ...

Tarsus Pharmaceuticals has performed an aggressive marketing push for Xdemvy in Demodex blepharitis. Read why TARS stock is a ...

FIRST ON FOX: Shortly after announcing a strategy to go after deceptive direct-to-consumer advertising by the pharmaceutical industry, Robert F. Kennedy Jr. and the Department of Health and Human ...